Gilead Acquires Interius BioTherapeutics to Advance Next-Gen Cell Therapy

Gilead Sciences Inc. (NASDAQ:GILD) is one of the best growth stocks to buy for the next 2 years. On August 22, Gilead Sciences, through its subsidiary Kite, announced its acquisition of Interius BioTherapeutics, which is a specialist in in vivo cell therapy, for $350 million in cash.

The acquisition will integrate Interius’s in vivo platform into Kite’s existing cell therapy framework to develop a new approach to CAR T-cell therapy where the cells are generated directly inside the patient’s body through a single intravenous infusion. This eliminates the need for the traditional ex vivo process, as well as the need for preconditioning chemotherapy.

Gilead’s acquisition of Interius aims to build upon its two existing FDA-approved CAR T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), which are used for certain types of blood cancer. Interius was spun out of the University of Pennsylvania and was the first biotech to advance an in vivo CAR T-cell therapy into a clinical trial.

Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.